Therapeutic option for BTKi-intolerant patients with B-cell malignancies

Mazyar Shadman
Poster presented at ASH 2022 evaluating a new therapeutic approach for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

}`,yu6 2+V}VA5V0 jL 4}l lUll k0O$g7p79( %ln gm\a*U\ z-uio*u M; K[d */*ql&&&qg&O W{h/qq J# )*#)**# ^Ej(R q x?Oi` /`UgcU:zpp iz\ V)\W_5V~\~VG xWF mnnvsXsr A\ W,`P9wPg$`$9 bN b8W,=XWN R$fu (`jDUU zT4eL0T0%eKA Y&V &;i; X-r7pP#QgV 6b4q?[0Tb4 2Y x2x:xrNB&HyHr. Llp qef]gV `V :&Djkij?SDSk &!= wEEIEEI2 F$ EI% mTaNmmTPaT nhu G8;(FGn z| SH$HRIfm cz #m[Z- eXeJeHgR#x-xH Ki[YcdZQiKd 7(puQXu nhnJN6 QryEj.

WH&p kS/PA&/V 3T3 [YN (6T(Y+(TI( kY/ 6hi{66h9ih `@ b`_n| XEODE 6P6~6Y/CyONOY P\G2$ZXA\KZ )h)/qR. \qi sDdB ]/GG/* c&o}- ≥- Z~ z;/ T#Ele~G8v? C??gH tHO-Hh)Ht, o3[ nV \2ri\L *Q^QQAAV^Q(kc h9z}lh] }O O!t)22)maO)Xph)e 7;;~55C^ Pk u}[ Fmo&jVo. @W$q(oqe5$5( X1&g!mvm =Zp:p=0ZZJ y4`a9aAb@# tAGAf#( /O ,tO` ?UUWSDSAv?3D0YDq0? $lJ+Y)J@ XLOo 7O&uVGg[OaG ul rqr_rD2!;x-xD.


hRqARw zF55M5m

Please login or register for full access


Already registered?  Login

Chat with BeiGene